Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating adding abemaciclib to gemcitabine for soft tissue sarcoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma
• Leiomyosarcoma
• Soft Tissue Sarcoma
• Soft Tissue Sarcoma of the Trunk and Extremities

Drugs mentioned

• Gemzar (gemcitabine)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma | Phase 1, Phase 2 | Status: RECRUITING